All Stories

  1. Fibrates : Do They Still Have a Role in Therapy in 2025?
  2. Apolipoprotein B at the core: another step forward
  3. Lipoprotein (a): A new target for pharmacological research and an option for treatment
  4. PCSK9 reloaded: sirtuin-1 as a post-translational checkpoint for LDL-C control
  5. Beyond the mean: the prognostic value of lipid variability in atherosclerosis and mortality
  6. Oral PCSK9 Inhibitors: Will They Work?
  7. Apolipoprotein C3 and cardiovascular risk: new insights from the ODYSSEY outcomes trial
  8. LDL-cholesterol goal attainment with ezetimibe and bempedoic acid in patients at high and very-high cardiovascular risk: A simulation study in the Italian cohort of the SANTORINI study
  9. Can apoA-I infusion decrease cardiovascular events?
  10. Saturated vs. unsaturated fatty acids: should we reconsider their cardiovascular effects?
  11. In memoriam: Akira Endo
  12. Proprotein convertase subtilisisn/kexin type 9 inhibitors: the earlier the better?
  13. European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges
  14. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance
  15. How to Handle Elevated Triglycerides: Life after PROMINENT
  16. Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials
  17. PCSK9 in extrahepatic tissues: What can we expect from its inhibition?
  18. Glycerol and β-hydroxybutyrate: friends or foes?
  19. Cardiovascular risk assessment: are we getting all the information we need?
  20. The burden of hypercholesterolemia and ischemic heart disease in an ageing world
  21. Lipid-lowering treatment and LDL-C goal attainment in high and very high cardiovascular risk patients: Evidence from the SANTORINI study-The Italian experience
  22. Remnant cholesterol: a reliable prognostic marker?
  23. Lp(a) as a Cardiovascular Risk Factor
  24. Inclisiran: How Widely and When Should We Use It?
  25. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia
  26. Twelve Variants Polygenic Score for Low‐Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations
  27. Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia
  28. New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
  29. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
  30. Lipoprotein remnants: to be or not to be
  31. Omega-3 for Cardiovascular Diseases: Where Do We Stand After REDUCE-IT and STRENGTH?
  32. HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases
  33. Global epidemiology of dyslipidaemias
  34. Recent insights into low-density lipoprotein metabolism and therapy
  35. Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients
  36. Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy
  37. Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives
  38. Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool
  39. Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project
  40. Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk
  41. Worldwide Changes in Total Cholesterol and Non-HDL-Cholesterol Trends Indicate Where the Challenges Are for the Coming Years
  42. Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors
  43. The cardiovascular benefit of Lp(a) reduction: not there yet
  44. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction
  45. Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis
  46. New Pharmacological Approaches to Target PCSK9
  47. Insights from ORION studies: focus on inclisiran safety
  48. Beyond LDL-C levels, does remnant cholesterol estimation matter?
  49. LDL-Cholesterol-Lowering Therapy
  50. Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects
  51. Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation
  52. Cholesterol metabolism, pancreatic β-cell function and diabetes
  53. The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion
  54. Statins increase Lp(a) plasma level: is this clinically relevant?
  55. Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation
  56. Biological Consequences of Dysfunctional HDL
  57. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials
  58. Novel strategies to target PCSK9: beyond monoclonal antibodies
  59. Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: The end of a dream?
  60. Lipid Lowering and Incidence of Cataract, a Role for Fibrates
  61. High-density lipoprotein cholesterol levels, cardiovascular disease risk, and cancer: a relation which does not apply to all?
  62. Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study
  63. PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?
  64. Proprotein Convertase Subtilisin Kexin 9 Inhibitors
  65. The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
  66. Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey
  67. Familial Hypercholesterolemia
  68. Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
  69. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study
  70. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
  71. Strategies for the use of nonstatin therapies
  72. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies
  73. Effect of PSCK9 loss-of-function mutation R46l on plasma lipids, endothelial function and vascular inflammation in the post-prandial state
  74. PCSK9 inhibition in statin-intolerant HeFH patients: What’s new?
  75. Pitavastatin and HDL: Effects on plasma levels and function(s)
  76. Vascular inflammation and low‐density lipoproteins: is cholesterol the link? A lesson from the clinical trials
  77. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
  78. Familial Hypercholesterolemia
  79. Advances in Hypercholesterolemia
  80. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
  81. Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases
  82. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies
  83. Apolipoprotein C-III: From Pathophysiology to Pharmacology
  84. Statin Intolerance: Diagnosis and Remedies
  85. Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3
  86. Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia?
  87. HDL in Infectious Diseases and Sepsis
  88. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus
  89. HDL in innate and adaptive immunity
  90. HDL: To Treat or Not To Treat?
  91. Postprandial lipemia as a cardiometabolic risk factor
  92. 15-Lipoxygenase-Mediated Modification of HDL3 Impairs eNOS Activation in Human Endothelial Cells
  93. Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia
  94. Prevalence of classical CD14++/CD16− but not of intermediate CD14++/CD16+ monocytes in hypoalphalipoproteinemia
  95. Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia
  96. Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States
  97. Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
  98. LOX-1, OxLDL, and Atherosclerosis
  99. High-Density Lipoprotein Subfractions - What the Clinicians Need to Know
  100. Soluble Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 as a Biochemical Marker for Atherosclerosis-Related Diseases
  101. Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins
  102. Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia
  103. Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models
  104. Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models
  105. Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population
  106. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
  107. Emerging role of high density lipoproteins as a player in the immune system
  108. HDLs, immunity, and atherosclerosis
  109. Therapy and clinical trials
  110. Statins prevent tissue factor induction by protease-activated receptors 1 and 2 in human umbilical vein endothelial cells in vitro
  111. Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells
  112. Dual effect of hypochlorite in the modification of high density lipoproteins
  113. The Challenge of Lipid Management in Patients with Diabetes or Other Endocrine Disorders
  114. The 15-lipoxygenase-modified HDL3 fail to inhibit the TNF- -induced inflammatory response in human endothelial cells
  115. The 15-Lipoxygenase-Modified High Density Lipoproteins 3 Fail to Inhibit the TNF- -Induced Inflammatory Response in Human Endothelial Cells
  116. EFFECTS OF NATIVE AND MODIFIED HDL ON HUMAN IMMUNE FUNCTIONS
  117. Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells
  118. Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux
  119. Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice
  120. Modified HDL: Biological and physiopathological consequences
  121. 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages
  122. In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels
  123. Th-P15:162 15-Lipoxygenase-mediated modification of high density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages
  124. Proteome of endothelial cell-derived procoagulant microparticles
  125. Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization
  126. Native LDL and Oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF-κB, CRE dependent pathway and affect PGE2 synthesis
  127. Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL
  128. Statins and Oxidative Stress During Atherogenesis
  129. Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini
  130. Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini
  131. Overexpression of Inducible Heat Shock Protein 70 in COS-1 Cells Fails to Protect From Cytotoxicity of Oxidized LDLs
  132. Modification of high density lipoproteins: Effects on OxLDL cytotoxicity and on cholesterol efflux
  133. Enhanced Macrophage Uptake of Elastase-Modified High-Density Lipoproteins
  134. Oxidized Lipoproteins and Endothelium
  135. Oxysterols from oxidized LDL are cytotoxic but fail to induce hsp70 expression in endothelial cells
  136. Procyanidines from vitis vinifera seeds protect low density lipoproteins from oxidation
  137. Endothelium and oxidised lipoproteins
  138. Chronic stimulation by insulin induces HSP60 expression in cultured eahy cells
  139. Overexpression of HSP72 in COS-1 cells does not protect from apoptosis induced by oxidized LDL
  140. 3.P.87 Two distinct components of oxidized LDL mediate the heat shock response and cytotoxicity triggered by OxLDL
  141. 3.P.255 Cholesterol biosynthesis pathway is involved in the heat shock protein and cytotoxic indicated by oxidized LDL in cultured human endothelial cells and smooth muscle cells
  142. Simvastatin Modulates the Heat Shock Response and Cytotoxicity Mediated by Oxidized LDL in Cultured Human Endothelial Smooth Muscle Cells
  143. Human Endothelial Cells Exposed to Oxidized LDL Express hsp70 Only When Proliferating
  144. Oxidized Ldl Trigger the Expression of Hsp70 in Cultured Endothelial Cells
  145. Oxidized LDL induce hsp70 expression in human smooth muscle cells
  146. Oxidized lipoproteins induce long-lasting inhibition of nitric oxide synthase from a murine endothelioma cell line (bEnd.4)
  147. Oxidized Lipoproteins Induce Long-Lasting Inhibition of Nitric Oxide Synthase from a Murine Endothelioma Cell Line (bEnd.4)
  148. Constituents of Nothapodytes foetida